sarcosine has been researched along with Amentia in 5 studies
cocobetaine: N-alkyl-betaine; cause of shampoo dermatitis
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (40.00) | 18.2507 |
| 2000's | 2 (40.00) | 29.6817 |
| 2010's | 1 (20.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Tsai, CH | 1 |
| Huang, HC | 1 |
| Liu, BL | 1 |
| Li, CI | 1 |
| Lu, MK | 1 |
| Chen, X | 1 |
| Tsai, MC | 1 |
| Yang, YW | 1 |
| Lane, HY | 1 |
| Spillantini, MG | 3 |
| Crowther, RA | 3 |
| Kamphorst, W | 1 |
| Heutink, P | 1 |
| van Swieten, JC | 1 |
| Hulette, CM | 1 |
| Pericak-Vance, MA | 1 |
| Roses, AD | 1 |
| Schmechel, DE | 1 |
| Yamaoka, LH | 1 |
| Gaskell, PC | 1 |
| Welsh-Bohmer, KA | 1 |
| Yasuda, M | 1 |
| Takamatsu, J | 1 |
| D'Souza, I | 1 |
| Kawamata, T | 1 |
| Hasegawa, M | 2 |
| Hasegawa, H | 1 |
| Tanimukai, S | 1 |
| Poorkaj, P | 1 |
| Varani, L | 1 |
| Varani, G | 1 |
| Iwatsubo, T | 2 |
| Goedert, M | 1 |
| Schellenberg, DG | 1 |
| Tanaka, C | 1 |
| Hayashi, S | 1 |
| Toyoshima, Y | 1 |
| Umeda, Y | 1 |
| Wakabayashi, K | 1 |
| Tokiguchi, S | 1 |
| Takahashi, H | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| [NCT01785628] | 30 participants (Actual) | Interventional | 2010-08-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The BDI-II is a 21-item self-report questionnaire assessing the current severity of depression symptoms. Each item is scored on a scale of 0 to 3 and the total score ranges from 0 to 63. With a higher score indicating more severe symptoms. (NCT01785628)
Timeframe: baseline to 8 weeks
| Intervention | Scores on a scale (Mean) | |||
|---|---|---|---|---|
| Baseline | V1(2 weeks) | V2(4 weeks) | V3(8 weeks) | |
| Placebo Capsule | 9.9 | 10.5 | 10.2 | 9.8 |
| Sarcosine Capsule | 14.3 | 15.6 | 15.8 | 17.5 |
The Behave-AD includes the assessment of symptoms and a global rating of caregiver distress. A total of 25 symptoms in 7 clusters are rated: paranoid and delusional ideation, hallucinations, aggressiveness, activity disturbances, diurnal rhythm disturbances, affective disturbances and anxieties, and phobias. Caregivers rate behavioral symptoms over the preceding 2 weeks on a 0 to 3 scale. The caregiver also determines a global assessment of caregiver distress on a scale of 0 to 3. The maximum score is 75 and with a higher score indicating more severe symptoms. (NCT01785628)
Timeframe: baseline to 8 weeks
| Intervention | Scores on a scale (Mean) | |||
|---|---|---|---|---|
| Baseline | V1(2 weeks) | V2(4 weeks) | V3(8 weeks) | |
| Placebo Capsule | 7.9 | 5.2 | 6.8 | 6.4 |
| Sarcosine Capsule | 10.0 | 8.4 | 7.5 | 9.4 |
The CDR is a 5-point scale used to characterize six domains of cognitive and functional performance applicable to Alzheimer disease and related dementias: Memory, Orientation, Judgment & Problem Solving, Community Affairs, Home & Hobbies, and Personal Care. With a higher score indicating more severe symptoms. (NCT01785628)
Timeframe: baseline to 8 weeks
| Intervention | Scores on a scale (Mean) | ||
|---|---|---|---|
| Baseline | V2(4 weeks) | V3(8 weeks) | |
| Placebo Capsule | 1.1 | 1.1 | 1.1 |
| Sarcosine Capsule | 2.3 | 2.1 | 2.0 |
The Cognitive Abilities Screening Instrument (CASI) has a score range of 0 to 100 and provides quantitative assessment on attention, concentration, orientation, short-term memory, long-term memory, language abilities, visual construction, list-generating fluency, abstraction, and judgment. With a higher score indicating Symptom improvement. (NCT01785628)
Timeframe: baseline to 8 weeks
| Intervention | Scores on a scale (Mean) | ||
|---|---|---|---|
| Baseline | V2(4 weeks) | V3(8weeks) | |
| Placebo Capsule | 63.9 | 63.9 | 63.9 |
| Sarcosine Capsule | 50.9 | 53.1 | 52.4 |
The HAM-D is a 21-item rating scaled which includes an emphasis on behavioral symptoms and somatic complaints that neglects self-reported feelings of distress; and an intermingling of frequency and intensity of symptoms. The total score ranges from 0 to 64: ten items are ranked on a scale from 0 to 4; 9 items are ranked 0 to 2; and 2 items are ranked 0 to 3. With a higher score indicating more severe symptoms. (NCT01785628)
Timeframe: baseline to 8 weeks
| Intervention | Scores on a scale (Mean) | |||
|---|---|---|---|---|
| Baseline | V1(2 weeks) | V2(4 weeks) | V3(8 weeks) | |
| Placebo Capsule | 7.6 | 7.6 | 7.8 | 7.3 |
| Sarcosine Capsule | 11.8 | 9.9 | 10.1 | 11.0 |
The NPI scale has 12 domains: delusions, hallucinations, agitation, dysphoria, anxiety, apathy, irritability, euphoria, disinhibition, aberrant motor behavior, night-time behavior disturbances, and appetite and eating abnormalities. The total score ranges from 0 to 144, where the score for a domain is defined as the product of frequency (range: 1-4) and severity (range: 1-3). Each domain has a maximum score of 12 and with a higher score indicating more severe symptoms. (NCT01785628)
Timeframe: baseline to 8 weeks
| Intervention | Scores on a scale (Mean) | |||
|---|---|---|---|---|
| Baseline | V1(2weeks) | V2(4 weeks) | V3(8 weeks) | |
| Placebo Capsule | 14.9 | 14.1 | 11.7 | 13.3 |
| Sarcosine Capsule | 18.4 | 14.8 | 12.4 | 18.1 |
The PDQ-39 contains 39-items covering 8 discrete dimensions: mobility, activities of daily living, emotional well-being, stigma, social support, cognitions, communication, and bodily discomfort. Each question is scored on a 5-point scale and recoded to 0 to 4 for the analysis. The total score can range from 0 to 132 and with a higher score indicating more severe symptoms. (NCT01785628)
Timeframe: baseline to 8 weeks
| Intervention | Scores on a scale (Mean) | |||
|---|---|---|---|---|
| Baseline | V1(2 weeks) | V2(4 weeks) | V3(8 weeks) | |
| Placebo Capsule | 64.8 | 60.9 | 60.9 | 60.1 |
| Sarcosine Capsule | 68.0 | 67.9 | 65.9 | 63.7 |
Outcome is defined as change in total Unified Parkinson's Disease Rating Scale (UPDRS) between the baseline to 8 weeks. The UPDRS score has three parts, part I (Mentation, Behavior and Mood), Part II (Activities of Daily Living) and Part III (Motor Examination). Each consisting of questions answered on a 0-4 point scale. The minimum total score possible is 0 and the maximum total score possible is 176. Higher scores indicating more severe symptoms. (NCT01785628)
Timeframe: baseline to 8 weeks.
| Intervention | Scores on a scale (Mean) | |||
|---|---|---|---|---|
| baseline | V1(2-week) | V2(4-week) | V3(8-week) | |
| Placebo Capsule | 66.7 | 65.2 | 67.6 | 68.3 |
| Sarcosine Capsule | 71.6 | 67.9 | 69.3 | 71.3 |
1 trial available for sarcosine and Amentia
| Article | Year |
|---|---|
Activation of N-methyl-D-aspartate receptor glycine site temporally ameliorates neuropsychiatric symptoms of Parkinson's disease with dementia.
Topics: Aged; Aged, 80 and over; Dementia; Double-Blind Method; Female; Humans; Male; Middle Aged; Parkinson | 2014 |
4 other studies available for sarcosine and Amentia
| Article | Year |
|---|---|
Tau pathology in two Dutch families with mutations in the microtubule-binding region of tau.
Topics: Aged; Aged, 80 and over; Chromosomes, Human, Pair 17; Dementia; Detergents; Exons; Frontal Lobe; Hip | 1998 |
Neuropathological features of frontotemporal dementia and parkinsonism linked to chromosome 17q21-22 (FTDP-17): Duke Family 1684.
Topics: Adult; Age of Onset; Aged; Chromosomes, Human, Pair 17; Dementia; Female; Frontal Lobe; Humans; Immu | 1999 |
A novel mutation at position +12 in the intron following exon 10 of the tau gene in familial frontotemporal dementia (FTD-Kumamoto)
Topics: Brain; Brain Chemistry; Dementia; Detergents; DNA Mutational Analysis; Exons; Family Health; Female; | 2000 |
Late-onset frontotemporal dementia with a novel exon 1 (Arg5His) tau gene mutation.
Topics: Age of Onset; Aged; Aged, 80 and over; Dementia; Detergents; Exons; Humans; Inclusion Bodies; Male; | 2002 |